Latest Secondary Hyperparathyroidism (SHPT) News
Hemodialysis patients who undergo the procedure experience decreased risks of all-cause and cardiovascular mortality.
Researchers find link among patients with subclinical hyperthyroidism and euthyroid sick syndrome.
Younger age and longer dialysis vintage associated with greater likelihood of having the operation.
Switching from intravenous to oral alfacalcidol resulted in greater PTH suppression in patients with secondary hyperparathyroidism.
Researchers find a 'nominally significant' decrease in the risk of a composite outcome of death and nonfatal major cardiovascular events.
Phosphate level is a stronger predictor for increased mortality among hemodialysis (HD) patients than calcium and parathyroid hormone (PTH) levels.
Greater body mass index and waist circumference increases risk of secondary hyperparathyroidism, hyperphosphatemia, and hypertension.
NATIONAL HARBOR, Md.—Low and high levels of parathyroid hormone (PTH) are associated with hypercalcemia, according to a study of 106,760 hemodialysis patients presented at the National Kidney Foundation 2012 Spring Clinical Meetings suggest.
NATIONAL HARBOR, Md.—An investigational treatment safely and effectively lowers elevated plasma intact parathyroid hormone (iPTH) levels in patients with stage 3 or 4 chronic kidney disease and vitamin D deficiency, researchers reported at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Vitamin D deficiency is strongly associated with secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), according to data presented at the National Kidney Foundation (NKF) 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Laboratories can differ in their measurements of intact parathyroid hormone (iPTH) levels, resulting in varying treatment approaches for hemodialysis (HD) patients depending on the iPTH assay used, researchers reported at the National Kidney Foundation Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Levels of 25-hydroxyvitamin D (25D) higher than 20 ng/mL would be required to normalize intact parathyroid hormone (iPTH) in patients with stages 3 and 4 chronic kidney disease (CKD) with vitamin D insufficiency and secondary hyperparathyroidism, researchers concluded in a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Oral calcitriol is as effective as vitamin D analogues for treating secondary hyperparathyroidism (SHPT) in hemodialysis patients but is more cost effective, according to a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
The drug was more likely than cinacalcet to achieve a 50 percent or greater decrease in iPTH from baseline.
LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to data reported at the National Kidney Foundation's Spring Clinical Meetings.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
- Phosphate Binder Adherence Challenging for Dialysis Patients
- Transperineal Prostate Biopsy Better for PCa Risk Statification
- Androgen Deprivation for Localized Prostate Cancer Ups Cardiac Risks
- Upping Shock Wave Frequency Improves Ureteral Stone Clearance
- Prostate Cancer Diagnosis Raises Suicide Risk
- Preop ADT Could Potentially Eradicate High-Risk Prostate Tumors
- PCa Deaths Rare Among Low-Risk Patients on Active Surveillance
- Can Tight Blood Pressure Control Prevent Repeat Hemorrhagic Strokes?
- Joint Pain Linked to DPP-4 Inhibitor Use by Type 2 Diabetics
- Doctor Involvement Improves Obese Patients' Weight-Loss Efforts